Issued in 2015 – SCAAR

SCAAR Annual report 2014

Issued in 2015 – SCAAR Working group SCAAR 2014 Chair Stefan James, MD, PhD, Uppsala Deputy chair Bo Lagerqvist, MD, PhD, Uppsala Oskar Angerås, MD, Gothenburg Jörg Carlsson, MD, PhD, Kalmar Agneta Flinck, MD, PhD, Gothenburg Ole Fröbert, MD, PhD, Örebro Matthias Götberg, MD, PhD, Lund Robert Kastberg, MD, Gävle Johan Nilsson, MD, PhD, Umeå Göran Olivecrona, MD, PhD, Lund Elmir Omerovic, MD, PhD, Gothenburg Jonas Persson, MD, PhD, Stockholm Nawzad Saleh, MD, PhD, Stockholm

Issued in 2015 – SCAAR Figure 1. Overall number of procedures, 1982–2014.

Issued in 2015 – SCAAR Figure 2. Number of coronary angiographies per hospital, 2013 and 2014.

Issued in 2015 – SCAAR Figure 3. Number of coronary angiographies per inhabitants in the patient’s home county, 2014.

Issued in 2015 – SCAAR Figure 4. Number of ischaemic heart disease diagnoses (I20–I25) per inhabitants (from National Board of Health and Welfare statistical databases) in the patient’s home county, 2013.

Issued in 2015 – SCAAR Table 1. Indication for coronary angiography in detail, number and proportion of patients, 2014.

Issued in 2015 – SCAAR Figure 5. Frequency distribution of coronary angiography procedures according to age, 2014.

Issued in 2015 – SCAAR Figure 6. Number of coronary angiographies per age group and year, 2000–2014.

Issued in 2015 – SCAAR Figure 7. Distribution of PCI patients in relation to age and gender, (number above the bar), 2014.

Issued in 2015 – SCAAR Figure 8. Primary decision after coronary angiography in patients with three-vessel disease (left main stem stenoses and STEMI excluded), per healthcare region, 2014.

Issued in 2015 – SCAAR Figure 9. Primary decision following coronary angiography, 2000–2014.

Issued in 2015 – SCAAR Figure 10. Proportion of angiographic findings in patients with suspected ischaemic heart disease, per hospital, 2014.

Issued in 2015 – SCAAR Figure 11. Proportion of patients without angiographically significant stenoses with indication stable coronary artery disease, unstable angina, NSTEMI, STEMI, or unclear chest pain, according to gender and age group, 2014 (number of patients above the bar).

Issued in 2015 – SCAAR Figure 12. Proportion of risk factors in PCI patients, per year, 2000–2014.

Issued in 2015 – SCAAR Figure 13. Primary decision following coronary angiography in patients with left main stem stenosis, per year, 2003–2014 (diagnostic PCI, patients with STEMI or previous CABG and patients where surgery has been declined are excluded).

Issued in 2015 – SCAAR Figure 14. Primary decision after coronary angiography with finding of three-vessel disease in patients > 80 years with diabetes and stable coronary artery disease, per year, 2006–2014.

Issued in 2015 – SCAAR Figure 15. Primary decision following coronary angiography in patients with left main stem stenosis, per hospital with ≥ 10 patients, 2014 (diagnostic PCI, patients with STEMI or previous CABG and patients where surgery has been declined are excluded).

Issued in 2015 – SCAAR Figure 16. Primary decision after coronary angiography with finding of three-vessel disease in patients > 80 years with diabetes and stable coronary artery disease, per year, 2006–2014.

Issued in 2015 – SCAAR Figure 17. Number of PCIs per type and hospital, 2013 and 2014.

Issued in 2015 – SCAAR Figure 18. Number of PCIs per inhabitants in the patient’s home county, 2014.

Issued in 2015 – SCAAR Figure 19. Number of ischaemic heart disease diagnoses (I20-I25) per inhabitants (from National Board of Health and Welfare statistical databases), in the patient’s home county, 2013.

Issued in 2015 – SCAAR Figure 20. Proportional distribution of indication for PCI, per hospital, 2014.

Issued in 2015 – SCAAR Figure 21. Proportion of treated segment, per diagnosis, 2014.

Issued in 2015 – SCAAR Figure 22. Primary decision following coronary angiography in patients with suspected STEMI, 2000–2014.

Issued in 2015 – SCAAR Figure 23. PCI patients with indication of STEMI, 2000–2014.

Issued in 2015 – SCAAR Figure 24. Angiographic findings in STEMI patients, per year, 2000–2014.

Issued in 2015 – SCAAR Figure 25. Proportion of cardiogenic shock among PCI-treated STEMI patients, per year, 2000–2014 (diagnostics only excluded).

Issued in 2015 – SCAAR Figure 26. One-year mortality after PCI in STEMI patients, per year, 2005–2013 (mean value, 95 % CI).

Issued in 2015 – SCAAR Figure 27. Proportion of PCI patients with STEMI, per age group and year, 2000–2014.

Issued in 2015 – SCAAR Figure day mortality after PCI in STEMI patients, per age group, 2005–2014 (mean value, 95 % CI).

Issued in 2015 – SCAAR Figure day mortality after PCI in STEMI patients, per hospital, 2005–2014 (mean value, 95 % CI).

Issued in 2015 – SCAAR Figure 30. Primary decision after coronary angiography in STEMI patients, per health care region, 2014.

Issued in 2015 – SCAAR Figure 31. Trend in thrombus aspiration following PCI in STEMI patients, 2005–2014.

Issued in 2015 – SCAAR Figure 32. Proportion of indications for PCI treatment, per year, 2003–2014.

Issued in 2015 – SCAAR Figure 33. Primary decision after angiography for different indications, 2014.

Issued in 2015 – SCAAR Figure day mortality for different indications in PCI patients, 2014.

Issued in 2015 – SCAAR Figure 35. Distribution of waiting time (days from admission to PCI) for NSTEMI patients, 2014.

Issued in 2015 – SCAAR Figure 36. Distribution of waiting time (days from admission to PCI treatment) for NSTEMI patients according to hospitals hospitals with ≥ 10 patients, 2014.

Issued in 2015 – SCAAR Figure day mortality for PCI patients with NSTEMI in relation to hospital admission time to day of PCI, 2014.

Issued in 2015 – SCAAR Figure 38. Mean age of PCI-treated NSTEMI patients according to time from hospital admission to day of PCI, 2014.

Issued in 2015 – SCAAR Figure 39. Trend in 30-day mortality after PCI-treatment, 2003–2014.

Issued in 2015 – SCAAR Figure 40. Proportion of GP IIb/IIIa inhibitor/bivalirudin use before or during PCI in STEMI patients, per hospital, 2014.

Issued in 2015 – SCAAR Figure 41. Proportion of patients receiving a GP IIb/IIIa inhibitor and bivalirudin before or during PCI, per indication, 2014.

Issued in 2015 – SCAAR Figure 42. Proportion of GP IIb/IIIa inhibitor/bivalirudin use before or during PCI in STEMI patients, per year, 2014.

Issued in 2015 – SCAAR Figure 43. Anticoagulation (AC) treatment before or during PCI procedure in STEMI patients, 2006–2014.

Issued in 2015 – SCAAR Figure 44. AC treatment before or during PCI procedure in NSTEMI patients, 2006–2014.

Issued in 2015 – SCAAR Figure 45. AC treatment before or during PCI procedure in stable angina, 2006–2014.

Issued in 2015 – SCAAR Figure 46. Proportion of PCI patients with STEMI treated with P2Y12 receptor blockers, 2010–2014.

Issued in 2015 – SCAAR Figure 47. Proportion of PCI patients with STEMI treated with P2Y12 receptor blockers, per hospital, 2014.

Issued in 2015 – SCAAR Figure 48. Proportion of PCI patients with NSTEMI treated with P2Y12 receptor blockers, 2010–2014.

Issued in 2015 – SCAAR Figure 49. Proportion of PCI patients with NSTEMI treated with P2Y12 receptor blockers, per hospital, 2014.

Issued in 2015 – SCAAR Figure 50. Proportion of PCI patients with stable angina treated with P2Y12 receptor blockers, 2010–2014.

Issued in 2015 – SCAAR Figure 51. Proportion of PCI patients with stable angina treated with P2Y12 receptor blockers, per hospital, 2014.

Issued in 2015 – SCAAR Figure 52. Proportion of PCI involving the use of IVUS or OCT, per hospital, 2014.

Issued in 2015 – SCAAR Figure 53. Proportion of coronary angiography in stable coronary artery disease where FFR/iFR was used, per year, 2006–2014.

Issued in 2015 – SCAAR Figure 54. Proportion of coronary angiography in stable coronary artery disease where FFR/iFR was used, per hospital, 2014.

Issued in 2015 – SCAAR Figure 55. Interventions, various adjuvant therapies, and diagnostics following PCI, 2005–2014.

Issued in 2015 – SCAAR Figure 56. Proportion of restenoses of all PCI-treated stenoses, per year, 2003–2014.

Issued in 2015 – SCAAR Figure 57. Proportion of DES of all stents, per year, 2003–2014.

Issued in 2015 – SCAAR Figure 58. Proportion of DES of all stents, per hospital, 2014.

Issued in 2015 – SCAAR Figure 59. Number of different types of used DEB, 2009–2014.

Issued in 2015 – SCAAR Figure 60. Number of different types of DEB, 2014.

Issued in 2015 – SCAAR Figure 61. Puncture site in angiography/PCI patients, 2014.

Issued in 2015 – SCAAR Figure 62. Proportion of radial puncture in angiography/PCI, per year, 2003–2014.

Issued in 2015 – SCAAR Figure 63. Proportion of radial puncture in angiography/PCI in STEMI patients, per year, 2003–2014.

Issued in 2015 – SCAAR Figure 64. Proportion of puncture site in angiography/PCI, per hospital, 2014.

Issued in 2015 – SCAAR Figure 65. Proportion of bleedings at puncture site in PCI patients, per vascular closure device (≥ 50 uses), 2014 (number of bleedings above the bar, 95 % CI).

Issued in 2015 – SCAAR Figure 66. Proportion of complications in PCI patients, reported from the catheterisation lab, 2014 (number of complications above the bar, 95 % CI).

Issued in 2015 – SCAAR Figure 67. Proportion of complications in PCI patients with STEMI reported from the catheterisation lab, 2014 (number of complications above the bar, 95 % CI).

Issued in 2015 – SCAAR Figure 68. Proportion of complications in PCI patients reported from the ward, 2014 (number of complications above the bar, 95 % CI).

Issued in 2015 – SCAAR Figure 69. Proportion of bleedings in PCI patients reported from the ward, 2014 (number of bleedings above the bar, 95 % CI).

Issued in 2015 – SCAAR Figure 70. Proportion of bleedings reported from ward in angio­graphy/PCI patients, per puncture site and year, 2008–2014.

Issued in 2015 – SCAAR Figure 71. Proportion and type of bleeding complications in angiography/PCI patients, per puncture site, 2014.

Issued in 2015 – SCAAR Figure 72. Proportion of bleeding complications in isolated angio­graphy and PCI patients, 2014 (number of bleeding complications above the bar, 95 % CI).

Issued in 2015 – SCAAR Figure 73. Proportion of complications in PCI patients reported from both catheterisation lab and ward, 2014 (number of complications above the bar).

Issued in 2015 – SCAAR Figure 74. Proportion of neurological complications in angiography/PCI, per age group, 2003–2014 (number of neurological complications above the bar, 95 % CI).

Issued in 2015 – SCAAR Figure 75. Proportion of neurological complications in angio­graphy/PCI patients, per puncture site and year, 2003–2014.

Issued in 2015 – SCAAR Figure 76. Median volume of contrast agent for angiography without simultaneous PCI, per hospital, 2014, excluding patients with previous CABG or other adjuvant investigations requiring contrast agent, e.g. LV-angiography are excluded.

Issued in 2015 – SCAAR Figure 77. Median volume of contrast agent for PCI (ad hoc or elective) per hospital, 2014.

Issued in 2015 – SCAAR Figure 78. Median fluoroscopy time in coronary angiography without simultaneous PCI per hospital, Patients with previous CABG were excluded.

Issued in 2015 – SCAAR Figure 79. Median fluoroscopy time in PCI (ad hoc or elective) per hospital, Patients with previous CABG were excluded.

Issued in 2015 – SCAAR Figure 80. Median radiation dose (μGym2) in angiography without simultaneous PCI, per hospital, Patients with previous CABG or other adjuvant investigations requiring contrast agent, e.g. LV-angiography are excluded.

Issued in 2015 – SCAAR Figure 81. Median radiation dose (μGym2) for PCI, 2014.

Issued in 2015 – SCAAR Figure 82. Number and type of indications for CT-angiography, 2014.

Issued in 2015 – SCAAR Figure 83. Proportion of findings in CT-angiography, per centre with ≥ 10 patients, 2014.

Issued in 2015 – SCAAR Figure 84. Proportion of patients with suspected coronary artery disease/unclear chest pain without angiographically significant stenoses at time for CT- angiography, according to gender and age group, 2014 (number of patients above the bar).

Issued in 2015 – SCAAR Figure 85. Radiation dose in prospective and retrospective ECG triggering in CT-angiography, Mean with 95 % CI.

Issued in 2015 – SCAAR Figure 86. Median radiation dose in CT-angiography, per hospital with ≥ 10 values, 2014.

Issued in 2015 – SCAAR Figure 87. Trend in median radiation dose in CT-angiography, 2008–2014.

Issued in 2015 – SCAAR Figure 88. iFR SWEDEHEART – Total number of randomised patients.

Issued in 2015 – SCAAR Figure 89. iFR SWEDEHEART – Total number of included patients.

Issued in 2015 – SCAAR Figure 90. VALIDATE – Randomisation prognosis and actual randomisation.